| Objective: Viral hepatitis is a global health problem.Hepatitis B(HB)and hepatitis C(HC)are not negligible causes of liver-related deaths.There is also controversy as to whether COVID-19 causes liver function impairment.This study aimed to explore and analyse the excellent publications in the field of HB,HC,COVID-19 and liver injury in the last decade,to identify their trends and research hotspots,and to sort out the disciplinary knowledge base to provide new insights to help scientific research.Methods: Papers related to HB,HC,COVID-19 and liver injury from January 1,2013,to December 31,2022,were searched in the Web of Science Core Collection(Wo SCC),respectively.The original articles and reviews were selected as the basis for this analysis study.Then,sorted by citations in descending order,the top 1000 records were taken for research.Bibliometric visualisation was performed via VOSviewer and Cite Space,and analysed separately for HB,HC,COVID-19 and liver injury research in terms of countries’,institutions’,authors’ output,collaborations,research hotspots,and cutting-edge trends.Results:(1)A total of 86 countries and 1,643 institutions contributed to HB research.China had the highest scientific output(43.4%),with 9 of the top 10 institutions located in China,and has formed extensive collaborations with the USA.Hepatology published the largest number of HB-related articles(n=116).Gastroenterology had the highest impact factor(IF)(IF=33.883)among the top10 journals in terms of publications and has a high academic quality.Zoulim F was the most prolific author(n=27).“Hepatocellular carcinoma”,“infection”,“surface antigen”,“therapy”,and “lamivudine” were the high-frequency occurrence keywords which represented research hotspots.The recent keywords with the strongest citation bursts contain “nucleotide analogue therapy”,“guideline”,“closed circular DNA”,“Hepatitis B virus(HBV)corerelated antigen”,“epigenetic regulation”,“innate immunity”,and “hepatitis B virus X protein” represent the research frontiers.Future research will continue to focus on antiviral therapy for HB,particularly the clinical cure.(2)The top1,000 articles on HC research were distributed across 81 countries and 1,916 institutions.There has been close cooperation between the USA and France.The USA had the highest number of articles(56.6%),where 9 of the top 10 institutions are located,which is the leading driver of HC research.Hepatology had the highest number of publications(n=134)and was cited most frequently.Annals of Internal Medicine had the fifth highest number of publications but the highest IF(IF=51.598).Dore GJ was the most prolific author(n=29).“Infection”,“sustained virological response(SVR)”,“ribavirin”,“sofosbuvir”and “hepatocellular carcinoma” are high-frequency occurrence keywords that represent the hotspots in HC research over the past decade.The recent keywords with the strongest citation bursts contain “sofosbuvir",“ledipasvir”,“open-label”,“direct-acting antiviral”,and “inject drug” which provide clues to the research frontiers.Glecaprevir for HC-related research will be the biggest hotspot in the future.(3)A total of 41 countries and 308 institutions are involved in the study of COVID-19 and liver injury.China(40%)contributed the most,followed by the USA(18.33%).The largest number of relevant articles was published in the World Journal of Gastroenterology(n=8,IF=5.374).There were no significant differences in contributions by authors for the time being.high frequency co-occurring keywords such as COVID-19,liver injury,SARS-Co V-2,and prognosis represented research hotspots.research on COVID-19 and liver failure may become the forefront.Conclusions:(1)A visual analysis of the HB study found that the USA and China have developed extensive international cooperation over the past decade.Existing research has focused on issues related to nucleotide analogue therapy,lamivudine,HBV closed circular DNA,HBV core-related antigen,epigenetic regulation,and hepatitis B virus X protein.Their treatment and intervention strategies are major trends for future research.(2)The visual analysis of the HC study shows that the United States is the main driver of research in this field,mainly in close cooperation with France.Treatment with direct-acting antiviral drugs and achieving SVR is the focus of HC treatment,and relevant research is currently focusing on issues such as sofosbuvir,ledipasvir,open-label trials,and people who inject drugs.The safety and efficacy of glecaprevir is a major research trend in HC treatment.(3)There are relatively few studies on COVID-19 and liver injury.The evidence for liver damage due to SARS-Co V-2 is not yet sufficient.The main mechanisms may be drug use,immune system activation,cytokine storm,etc.Due to its possible long-term liver injury effects,more studies are needed to provide recommendations for treating people with comorbid chronic liver disease or even liver failure. |
PDF Full Text Request